New edited immune cell therapy helps patients beat aggressive blood cancer
BBC - 09-Dec-2025This approach may help people whose cancer does not respond to standard care
Previously the Live Forever Club — same community, now with a sharper mission for life extension
This approach may help people whose cancer does not respond to standard care
TC BioPharm’s Phase 2B trial shows TCB008 is safe with promising early effects in AML
Base editing can soon be a part in taking control of our genomes to fight genetic diseases
No resources found!
No blog posts found!